AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.86 |
Market Cap | 194.56M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.25 |
PE Ratio (ttm) | -3.43 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.87 |
Volume | 744,660 |
Avg. Volume (20D) | 1,372,075 |
Open | 0.93 |
Previous Close | 0.92 |
Day's Range | 0.82 - 0.94 |
52-Week Range | 0.50 - 1.60 |
Beta | undefined |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...
Analyst Forecast
According to 5 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 948.22% from the latest price.
Next Earnings Release
Analysts project revenue of $7.02M, reflecting a n/a YoY growth and earnings per share of -0.17, making a -19.05% decrease YoY.